206 related articles for article (PubMed ID: 28867118)
21. Diuretic 18F-Fluorodeoxyglucose PET/Computed Tomography in Evaluation of Genitourinary Malignancies.
Agarwal KK; Roy SG; Kumar R
PET Clin; 2016 Jan; 11(1):39-46. PubMed ID: 26590442
[TBL] [Abstract][Full Text] [Related]
22. Present and future role of FDG-PET/CT imaging in the management of head and neck carcinoma.
Kitajima K; Suenaga Y; Sugimura K
Jpn J Radiol; 2015 Dec; 33(12):776-89. PubMed ID: 26507982
[TBL] [Abstract][Full Text] [Related]
23. Applications of Fluorodeoxyglucose PET/Computed Tomography in the Assessment and Prediction of Radiation Therapy-related Complications.
Houshmand S; Boursi B; Salavati A; Simone CB; Alavi A
PET Clin; 2015 Oct; 10(4):555-71. PubMed ID: 26384600
[TBL] [Abstract][Full Text] [Related]
24. Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging-prospective study.
Lee JR; Kim JS; Roh JL; Lee JH; Baek JH; Cho KJ; Choi SH; Nam SY; Kim SY
Radiology; 2015 Mar; 274(3):764-71. PubMed ID: 25405771
[TBL] [Abstract][Full Text] [Related]
25. Fluorodeoxyglucose positron emission tomography with computed tomography detects greater metabolic changes that are not represented by plain radiography for patients with osteonecrosis of the jaw.
Fleisher KE; Raad RA; Rakheja R; Gupta V; Chan KC; Friedman KP; Mourtzikos KA; Janal M; Glickman RS
J Oral Maxillofac Surg; 2014 Oct; 72(10):1957-65. PubMed ID: 25053572
[TBL] [Abstract][Full Text] [Related]
26. FDG PET/MR in initial staging of sarcoma: Initial experience and comparison with conventional imaging.
Platzek I; Beuthien-Baumann B; Schramm G; Maus J; Laniado M; Kotzerke J; van den Hoff J; Schuler M
Clin Imaging; 2017; 42():126-132. PubMed ID: 27951459
[TBL] [Abstract][Full Text] [Related]
27. Personalized Management Approaches in Lymphoma: Utility of Fluorodeoxyglucose-PET Imaging.
Ayers EC; Fardin S; Gholami S; Alavi A; Mato AR
PET Clin; 2016 Jul; 11(3):209-18. PubMed ID: 27321026
[TBL] [Abstract][Full Text] [Related]
28. Role of MR Imaging and FDG PET/CT in Selection and Follow-up of Patients Treated with Pelvic Exenteration for Gynecologic Malignancies.
Lakhman Y; Nougaret S; Miccò M; Scelzo C; Vargas HA; Sosa RE; Sutton EJ; Chi DS; Hricak H; Sala E
Radiographics; 2015; 35(4):1295-313. PubMed ID: 26172364
[TBL] [Abstract][Full Text] [Related]
29. (18)F-FDG PET/CT imaging in granulomatosis with polyangiitis.
De Geeter F; Gykiere P
Hell J Nucl Med; 2016; 19(1):5-6. PubMed ID: 26929934
[TBL] [Abstract][Full Text] [Related]
30. Hybrid MR-PET in Neuroimaging.
Bisdas S; Lá Fougere C; Ernemann U
Clin Neuroradiol; 2015 Oct; 25 Suppl 2():275-81. PubMed ID: 26227618
[TBL] [Abstract][Full Text] [Related]
31. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
[TBL] [Abstract][Full Text] [Related]
32. FDG PET/CT Imaging of Carotid Atherosclerosis.
Ali A; Tawakol A
Neuroimaging Clin N Am; 2016 Feb; 26(1):45-54. PubMed ID: 26610659
[TBL] [Abstract][Full Text] [Related]
33. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N
Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792
[TBL] [Abstract][Full Text] [Related]
34. PET/Computed Tomography in the Diagnosis and Staging of Gastric Cancers.
Malibari N; Hickeson M; Lisbona R
PET Clin; 2015 Jul; 10(3):311-26. PubMed ID: 26099669
[TBL] [Abstract][Full Text] [Related]
35. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging--pilot study.
Schwenzer NF; Schraml C; Müller M; Brendle C; Sauter A; Spengler W; Pfannenberg AC; Claussen CD; Schmidt H
Radiology; 2012 Aug; 264(2):551-8. PubMed ID: 22653189
[TBL] [Abstract][Full Text] [Related]
36. (18)F-Fluorodeoxyglucose PET/MR Imaging in Lymphoma.
Platzek I
PET Clin; 2016 Oct; 11(4):363-73. PubMed ID: 27593243
[TBL] [Abstract][Full Text] [Related]
37. [Why is PET/CT essential in urooncology?].
Borbély K; Géczi L; Kásler M
Magy Onkol; 2013 Dec; 57(4):282-96. PubMed ID: 24353995
[TBL] [Abstract][Full Text] [Related]
38. PET/MR Imaging in Musculoskeletal Precision Imaging - Third wave after X-Ray and MR.
Hancin EC; Borja AJ; Nikpanah M; Raynor WY; Haldar D; Werner TJ; Morris MA; Saboury B; Alavi A; Gholamrezanezhad A
PET Clin; 2020 Oct; 15(4):521-534. PubMed ID: 32768369
[TBL] [Abstract][Full Text] [Related]
39. Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT).
Cameron K; Golan S; Simpson W; Peti S; Roayaie S; Labow D; Kostakoglu L
Abdom Imaging; 2011 Aug; 36(4):463-71. PubMed ID: 21465110
[TBL] [Abstract][Full Text] [Related]
40. Image-guided Treatment in the Hepatobiliary System: Role of Imaging in Treatment Planning and Posttreatment Evaluation.
Bajpai S; Kambadakone A; Guimaraes AR; Arellano RS; Gervais DA; Sahani D
Radiographics; 2015; 35(5):1393-418. PubMed ID: 26252365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
